Finance

Lists
AMGN:NASDAQ
Amgen Inc
၄၀၃.၀၄ US$
-၁.၀၄%
(-၄.၂၃) 1D
၄၀၃.၀၄ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၂, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN...
Open
၄၁၀.၁၆ US$
High
၄၁၀.၁၆ US$
Low
၄၀၁.၉၆ US$
Mkt. cap
ဋေ ၂.၁၈ သ
Avg. vol.
၂.၉၁ သန်း
Volume
၃.၅၁ သန်း
Dividend
၂.၅၀%
Quarterly dividend
၂.၅၂ US$
Ex-dividend date
၂၀၂၆ ဩ ၂၁
P/E ratio
၂၅.၀၃
52-wk high
၄၄၇.၀၁ US$
52-wk low
၂၈၈.၀၀ US$
EPS
၁၆.၁၀ US$
Beta
၀.၄၁
Shares outstanding
၅၄.၀၆ ကုဋေ
No. of employees
၃ သောင်း
Open
၄၁၀.၁၆ US$
High
၄၁၀.၁၆ US$
Low
၄၀၁.၉၆ US$
Mkt. cap
ဋေ ၂.၁၈ သ
Avg. vol.
၂.၉၁ သန်း
Volume
၃.၅၁ သန်း
Dividend
၂.၅၀%
Quarterly dividend
၂.၅၂ US$
Ex-dividend date
၂၀၂၆ ဩ ၂၁
P/E ratio
၂၅.၀၃
52-wk high
၄၄၇.၀၁ US$
52-wk low
၂၈၈.၀၀ US$
EPS
၁၆.၁၀ US$
Beta
၀.၄၁
Shares outstanding
၅၄.၀၆ ကုဋေ
No. of employees
၃ သောင်း
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
ပြီးခဲ့သည့် ၉ နာရီ
Amgen announces Sjögren's results as Amgen stock trades flat at EUR 358.63
The Motley Fool
The Motley Fool
·
ပြီးခဲ့သည့် ၁၀ နာရီ
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၃ ရက်
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees၃.၁၅ သောင်း
Founded၁၉၈၀
Headquartersသောင်စင်အုက်စ်, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteamgen.com
Analyst ratings
Based on 27 analysts giving stock ratings to AMGN in the past 3 months
Buy
Buy
9
Hold
16
Sell
2
12-month forecast
Based on 27 Wall Street analysts offering 12 month price targets for AMGN in the last 3 months.
Highest
Current ၄၀၃.၀၄ US$
၅၀၀.၀၀ US$ (+၂၄.၀၆%)
Average
၄၀၁.၃၉ US$ (-၀.၄၁%)
Lowest
၂၃၀.၀၀ US$ (-၄၂.၉၃%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mohit Bansal
Wells Fargo
Hold
Maintained
၄၃၅.၀၀ US$
+၇.၉%
10/02/2026
Louise Chen
Scotiabank
Buy
Maintained
၅၀၀.၀၀ US$
+၂၄.၁%
09/29/2026
Christopher Raymond
Raymond James
Hold
Maintained
-
-
09/24/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
09/23/2026
Unknown Analyst
Jefferies
Hold
Maintained
၄၁၀.၀၀ US$
+၁.၇%
09/23/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
၄၅၀.၀၀ US$
+၁၁.၇%
09/22/2026
David Amsellem
Piper Sandler
Buy
Reiterated
၄၅၇.၀၀ US$
+၁၃.၄%
09/23/2026
Gregory Renza
Truist Financial
Hold
Maintained
-
-
09/23/2026
Gary Nachman
Canaccord Genuity
Hold
Maintained
၃၈၄.၀၀ US$
-၄.၇%
09/23/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
၃၆၂.၀၀ US$
-၁၀.၂%
09/22/2026
Tazeen Ahmad
Bank of America Securities
Sell
Maintained
၃၁၇.၀၀ US$
-၂၁.၃%
09/22/2026
Yaron Werber
TD Cowen
Buy
Reiterated
၄၅၂.၀၀ US$
+၁၂.၁%
09/22/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/22/2026
Geoff Meacham
Citi
Hold
Maintained
၄၀၅.၀၀ US$
+၀.၅%
09/23/2026
Evan Seigerman
BMO Capital
Hold
Maintained
၄၅၀.၀၀ US$
+၁၁.၇%
09/16/2026
Michael Yee
UBS
Buy
Reiterated
၄၃၀.၀၀ US$
+၆.၇%
09/17/2026
Emily Field
Barclays
Hold
Maintained
၃၈၀.၀၀ US$
-၅.၇%
09/17/2026
Morten Herholdt
HSBC
Hold
Downgraded
၄၂၅.၀၀ US$
+၅.၄%
09/09/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
၄၀၀.၀၀ US$
-၀.၈%
09/05/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
၄၆၀.၀၀ US$
+၁၄.၁%
08/18/2026
Salim Syed
Mizuho Securities
Hold
Maintained
၃၅၂.၀၀ US$
-၁၂.၇%
08/17/2026
Chris Schott
J.P. Morgan
Hold
Maintained
၃၅၀.၀၀ US$
-၁၃.၂%
08/06/2026
Vamil Divan
Guggenheim
Hold
Maintained
၃၈၈.၀၀ US$
-၃.၇%
08/07/2026
Courtney Breen
Bernstein
Hold
Maintained
၃၄၅.၀၀ US$
-၁၄.၄%
08/05/2026
Jay Olson
Oppenheimer
Buy
Maintained
၄၅၀.၀၀ US$
+၁၁.၇%
08/05/2026
Luca Issi
RBC Capital
Buy
Maintained
၄၀၀.၀၀ US$
-၀.၈%
08/05/2026
Brian Skorney
Robert W. Baird
Sell
Maintained
၂၃၀.၀၀ US$
-၄၂.၉%
08/05/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
၃၇၅.၀၀ US$
-၇%
05/07/2026
Hans Engel
Erste Group
Hold
Downgraded
-
-
05/05/2026
Unknown Analyst
Raymond James
Hold
Reiterated
-
-
05/01/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/01/2026
Unknown Analyst
J.P. Morgan
Hold
Initiated
၃၀၀.၀၀ US$
-၂၅.၆%
05/01/2026
Unknown Analyst
Canaccord Genuity
Hold
Initiated
၃၆၆.၀၀ US$
-၉.၂%
04/21/2026
Akash Tewari
Jefferies
Hold
Initiated
၃၅၀.၀၀ US$
-၁၃.၂%
03/10/2026
Unknown Analyst
Argus Research
Buy
Maintained
၄၀၀.၀၀ US$
-၀.၈%
02/06/2026
Last report
၂၀၂၆ ဩ ၄
Fiscal period
Q2 2026
EPS / Est. (USD)
၆.၂၉ US$ / ၅.၆၂ US$
+၁၁.၉၇%beat
Revenue / Est. (USD)
ဋေ ၁.၀၁ ထ / ၉၄၂.၀၂ ဋေ
+၆.၇၃%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၉၅၅.၇၀ ဋေ
၉၈၆.၆၀ ဋေ
၈၆၁.၈၀ ဋေ
ဋေ ၁.၀၁ ထ
Cost of goods sold
၂၇၄.၄၀ ဋေ
၂၆၇.၆၀ ဋေ
၂၄၉.၇၀ ဋေ
၂၇၅.၁၀ ဋေ
Cost of revenue
၂၇၄.၄၀ ဋေ
၂၆၇.၆၀ ဋေ
၂၄၉.၇၀ ဋေ
၂၇၅.၁၀ ဋေ
Research and development expenses
၁၉၀.၀၀ ဋေ
၂၁၄.၂၀ ဋေ
၁၇၁.၉၀ ဋေ
၁၈၆.၈၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၇၂.၀၀ ဋေ
၁၉၅.၂၀ ဋေ
၁၆၀.၂၀ ဋေ
၁၇၄.၅၀ ဋေ
Operating expense
၃၅၄.၉၀ ဋေ
၄၁၇.၆၀ ဋေ
၃၂၀.၈၀ ဋေ
၃၇၂.၉၀ ဋေ
Total operating expenses
၆၂၉.၃၀ ဋေ
၆၈၅.၂၀ ဋေ
၅၇၀.၅၀ ဋေ
၆၄၈.၀၀ ဋေ
Operating income
၃၂၆.၄၀ ဋေ
၃၀၁.၄၀ ဋေ
၂၉၁.၃၀ ဋေ
၃၅၇.၄၀ ဋေ
Other non operating income
၁၈.၁၀ ကုဋေ
၁၄.၃၀ ကုဋေ
၁၉.၂၀ ကုဋေ
၁၄.၅၀ ကုဋေ
EBT including unusual items
၃၉၂.၁၀ ဋေ
၁၅၁.၄၀ ဋေ
၂၀၈.၄၀ ဋေ
၂၇၆.၈၀ ဋေ
EBT excluding unusual items
၂၇၂.၁၀ ဋေ
၂၅၀.၉၀ ဋေ
၂၃၇.၁၀ ဋေ
၃၀၅.၅၀ ဋေ
Income tax expense
၇၀.၅၀ ကုဋေ
၁၈.၁၀ ကုဋေ
၂၆.၅၀ ကုဋေ
၃၉.၃၀ ကုဋေ
Effective tax rate
၁၇.၉၈%
၁၁.၉၆%
၁၂.၇၂%
၁၄.၂၀%
Other operating expenses
-၇.၁၀ ကုဋေ
၈.၂၀ ကုဋေ
-၁၁.၃၀ ကုဋေ
၁၁.၆၀ ကုဋေ
Net income
၃၂၁.၆၀ ဋေ
၁၃၃.၃၀ ဋေ
၁၈၁.၉၀ ဋေ
၂၃၇.၅၀ ဋေ
Net profit margin
၃၃.၆၅%
၁၃.၅၁%
၂၁.၁၁%
၂၃.၆၂%
Earnings per share
၅.၆၄
၅.၂၉
၅.၁၅
၆.၂၉
Interest and investment income
-
၄၀.၈၀ ကုဋေ
-
-
Interest expense
-၆၈.၅၀ ကုဋေ
-၁၀၆.၁၀ ဋေ
-၆၅.၇၀ ကုဋေ
-၆၇.၃၀ ကုဋေ
Net interest expenses
-၆၈.၅၀ ကုဋေ
-၆၅.၃၀ ကုဋေ
-၆၅.၇၀ ကုဋေ
-၆၇.၃၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၄၅၇.၁၀ ဋေ
၄၀၂.၂၀ ဋေ
၄၀၂.၉၀ ဋေ
၄၆၈.၆၀ ဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ